<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Germain DP</submitter><funding>NICHD NIH HHS</funding><funding>NCRR NIH HHS</funding><funding>NIDDK NIH HHS</funding><pagination>306-12</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC2039995</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>8(6)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Fabry disease (OMIM 301500) is an X-linked inborn error of glycosphingolipid metabolism resulting from mutations in the alpha-galactosidase A (alpha-Gal A) gene. The disease is phenotypically heterogeneous with classic and variant phenotypes. To assess the molecular heterogeneity, define genotype/phenotype correlations, and for precise carrier identification, the nature of the molecular lesions in the alpha-Gal A gene was determined in 40 unrelated families with Fabry disease.&lt;h4>Materials and methods&lt;/h4>Genomic DNA was isolated from affected males or obligate carrier females and the entire alpha-Gal A coding region and flanking sequences were amplified by PCR and analyzed by automated sequencing. Haplotype analyses were performed with polymorphisms within and flanking the alpha-Gal A gene.&lt;h4>Results&lt;/h4>Twenty new mutations were identified (G43R, R49G, M72I, G138E, W236X, L243F, W245X, S247C, D266E, W287C, S297C, N355K, E358G, P409S, g1237del15, g10274insG, g10679insG, g10702delA, g11018insA, g11185-delT), each in a single family. In the remaining 20 Fabry families, 18 previously reported mutations were detected (R49P, D92N, C94Y, R112C [two families], F113S, W162X, G183D, R220X, R227X, R227Q, Q250X, R301X, R301Q, G328R, R342Q, E358K, P409A, g10208delAA [two families]). Haplotype analyses indicated that the families with the R112C or g10208delAA mutations were not related. The proband with the D266E lesion had a severe classic phenotype, having developed renal failure at 15 years. In contrast, the patient with the S247C mutation had a variant phenotype, lacking the classic manifestations and having mild renal involvement at 64 years.&lt;h4>Conclusions&lt;/h4>These results further define the heterogeneity of alpha-Gal A mutations causing Fabry disease, permit precise heterozygote detection and prenatal diagnosis in these families, and provide additional genotype/phenotype correlations in this lysosomal storage disease.</pubmed_abstract><journal>Molecular medicine (Cambridge, Mass.)</journal><pubmed_title>Fabry disease: twenty novel alpha-galactosidase A mutations and genotype-phenotype correlations in classical and variant phenotypes.</pubmed_title><pmcid>PMC2039995</pmcid><funding_grant_id>R37 DK 34045</funding_grant_id><funding_grant_id>5 P30 HD28822</funding_grant_id><funding_grant_id>5 M01 RR00071</funding_grant_id><pubmed_authors>Germain DP</pubmed_authors><pubmed_authors>Desnick RJ</pubmed_authors><pubmed_authors>Shabbeer J</pubmed_authors><pubmed_authors>Cotigny S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Fabry disease: twenty novel alpha-galactosidase A mutations and genotype-phenotype correlations in classical and variant phenotypes.</name><description>&lt;h4>Background&lt;/h4>Fabry disease (OMIM 301500) is an X-linked inborn error of glycosphingolipid metabolism resulting from mutations in the alpha-galactosidase A (alpha-Gal A) gene. The disease is phenotypically heterogeneous with classic and variant phenotypes. To assess the molecular heterogeneity, define genotype/phenotype correlations, and for precise carrier identification, the nature of the molecular lesions in the alpha-Gal A gene was determined in 40 unrelated families with Fabry disease.&lt;h4>Materials and methods&lt;/h4>Genomic DNA was isolated from affected males or obligate carrier females and the entire alpha-Gal A coding region and flanking sequences were amplified by PCR and analyzed by automated sequencing. Haplotype analyses were performed with polymorphisms within and flanking the alpha-Gal A gene.&lt;h4>Results&lt;/h4>Twenty new mutations were identified (G43R, R49G, M72I, G138E, W236X, L243F, W245X, S247C, D266E, W287C, S297C, N355K, E358G, P409S, g1237del15, g10274insG, g10679insG, g10702delA, g11018insA, g11185-delT), each in a single family. In the remaining 20 Fabry families, 18 previously reported mutations were detected (R49P, D92N, C94Y, R112C [two families], F113S, W162X, G183D, R220X, R227X, R227Q, Q250X, R301X, R301Q, G328R, R342Q, E358K, P409A, g10208delAA [two families]). Haplotype analyses indicated that the families with the R112C or g10208delAA mutations were not related. The proband with the D266E lesion had a severe classic phenotype, having developed renal failure at 15 years. In contrast, the patient with the S247C mutation had a variant phenotype, lacking the classic manifestations and having mild renal involvement at 64 years.&lt;h4>Conclusions&lt;/h4>These results further define the heterogeneity of alpha-Gal A mutations causing Fabry disease, permit precise heterozygote detection and prenatal diagnosis in these families, and provide additional genotype/phenotype correlations in this lysosomal storage disease.</description><dates><release>2002-01-01T00:00:00Z</release><publication>2002 Jun</publication><modification>2024-10-19T09:26:01.918Z</modification><creation>2019-03-27T02:21:44Z</creation></dates><accession>S-EPMC2039995</accession><cross_references><pubmed>12428061</pubmed><doi>10.1007/BF03402156</doi></cross_references></HashMap>